Literature DB >> 22094534

Isotonic estimation of survival under a misattribution of cause of death.

Jinkyung Ha1, Alexander Tsodikov.   

Abstract

Several authors have indicated that incorrectly classified cause of death for prostate cancer survivors may have played a role in the observed recent peak and decline of prostate cancer mortality. Motivated by the suggestion we studied a competing risks model where other cause of death may be misattributed as a death of interest. We first consider a naïve approach using unconstrained nonparametric maximum likelihood estimation (NPMLE), and then present the constrained NPMLE where the survival function is forced to be monotonic. Surprising observations were made as we studied their small-sample and asymptotic properties in continuous and discrete situations. Contrary to the common belief that the non-monotonicity of a survival function NPMLE is a small-sample problem, the constrained NPMLE is asymptotically biased in the continuous setting. Other isotonic approaches, the supremum (SUP) method and the Pooled-Adjacent-Violators (PAV) algorithm, and the EM algorithm are also considered. We found that the EM algorithm is equivalent to the constrained NPMLE. Both SUP method and PAV algorithm deliver consistent and asymptotically unbiased estimator. All methods behave well asymptotically in the discrete time setting. Data from the Surveillance, Epidemiology and End Results (SEER) database are used to illustrate the proposed estimators.

Entities:  

Mesh:

Year:  2011        PMID: 22094534      PMCID: PMC4780425          DOI: 10.1007/s10985-011-9210-4

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  6 in total

1.  Estimation of competing risks with general missing pattern in failure types.

Authors:  Anup Dewanji; Debasis Sengupta
Journal:  Biometrics       Date:  2003-12       Impact factor: 2.571

2.  A nonidentifiability aspect of the problem of competing risks.

Authors:  A Tsiatis
Journal:  Proc Natl Acad Sci U S A       Date:  1975-01       Impact factor: 11.205

3.  The analysis of failure times in the presence of competing risks.

Authors:  R L Prentice; J D Kalbfleisch; A V Peterson; N Flournoy; V T Farewell; N E Breslow
Journal:  Biometrics       Date:  1978-12       Impact factor: 2.571

4.  Nonparametric estimation for partially-complete time and type of failure data.

Authors:  G E Dinse
Journal:  Biometrics       Date:  1982-06       Impact factor: 2.571

5.  Cancer surveillance series: interpreting trends in prostate cancer--part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality.

Authors:  E J Feuer; R M Merrill; B F Hankey
Journal:  J Natl Cancer Inst       Date:  1999-06-16       Impact factor: 13.506

6.  Effects of misattribution in assigning cause of death on prostate cancer mortality rates.

Authors:  Richard M Hoffman; S Noell Stone; William C Hunt; Charles R Key; Frank D Gilliland
Journal:  Ann Epidemiol       Date:  2003-07       Impact factor: 3.797

  6 in total
  4 in total

1.  Semiparametric estimation in the proportional hazard model accounting for a misclassified cause of failure.

Authors:  Jinkyung Ha; Alexander Tsodikov
Journal:  Biometrics       Date:  2015-06-23       Impact factor: 2.571

2.  Misclassification of the actual causes of death and its impact on analysis: A case study in non-small cell lung cancer.

Authors:  Kay See Tan
Journal:  Lung Cancer       Date:  2019-05-16       Impact factor: 5.705

3.  Nonparametric estimation of the cumulative incidence function under outcome misclassification using external validation data.

Authors:  Jessie K Edwards; Giorgos Bakoyannis; Constantin T Yiannoutsos; Margaret W Mburu; Stephen R Cole
Journal:  Stat Med       Date:  2019-10-24       Impact factor: 2.373

4.  Impact of and Correction for Outcome Misclassification in Cumulative Incidence Estimation.

Authors:  Giorgos Bakoyannis; Constantin T Yiannoutsos
Journal:  PLoS One       Date:  2015-09-02       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.